Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Rittmaster, R.S.
    5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction (2008), Best Pract. Res. Clin. Endocrinol. Metab., 22, 389-402.
    View publication on PubMed

Inhibitors

EC Number Inhibitors Comment Organism Structure
1.3.1.22 dutasteride 90% inhibition of type-2 and type-1 5alpha-reductases at clinical dosage of 0.5 mg/day Homo sapiens
1.3.1.22 finasteride 70% inhibition of type-2 5alpha-reductase at clinical dosage of 5.0 mg/day Homo sapiens

Organism

EC Number Organism UniProt Comment Textmining
1.3.1.22 Homo sapiens
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
1.3.1.22 liver
-
 Homo sapiens
-
1.3.1.22 prostate gland type-2 5alpha-reductase is only found in prostate and other genital tissues, enhancement of type-1 5alpha-reductase is enhanced in prostate cancer Homo sapiens
-
1.3.1.22 skin
-
 Homo sapiens
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
1.3.1.22 testosterone + NADPH + H+
-
 Homo sapiens 5alpha-dihydrotestosterone + NADP+
-
 ?

Synonyms

EC Number Synonyms Comment Organism
1.3.1.22 type-1 5alpha-reductase
-
 Homo sapiens
1.3.1.22 type-2 5alpha-reductase
-
 Homo sapiens

Cofactor

EC Number Cofactor Comment Organism Structure
1.3.1.22 NADPH
-
 Homo sapiens